In contrast, our GWAS explored various genes (AK3, TRPM3, CDH4, LINC00504, GRIN2D, HPGD, RC3H2, PCSK6, NPAS3, and DMXL2), which had significantly variable impacts on clinical outcomes of DOX after TACE in HCC patients. This evidence concerns the gene TRPM3 and hepatocellular carcinoma.